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Abstract
Background:  PX domains have specialized protein structures involved in binding of
phosphoinositides (PIs). Through binding to the various PIs PX domains provide site-specific
membrane signals to modulate the intracellular localisation and biological activity of effector
proteins. Several crystal structures of these domains are now available from a variety of proteins.
All PX domains contain a canonical core structure with main differences exhibited within the loop
regions forming the phosphoinositide binding pockets. It is within these areas that the molecular
basis for ligand specificity originates.
Results: We now report two new structures of PI3K-C2α PX domain that crystallised in a P3121
space group. The two structures, refined to 2.1 Å and 2.5 Å, exhibit significantly different
conformations of the phosphoinositide-binding loops. Unexpectedly, in one of the structures, we
have detected a putative-ligand trapped in the binding site during the process of protein purification
and crystallisation.
Conclusion: The two structures reported here provide a more complete description of the
phosphoinositide binding region compared to the previously reported 2.6 Å crystal structure of
human PI3K-C2α PX where this region was highly disordered. The structures enabled us to further
analyse PI specificity and to postulate that the observed conformational change could be related to
ligand-binding.
Background
Many cellular processes such as growth, signalling,
cytoskeletal rearrangement and membrane trafficking
depend upon lipid-protein interactions [1,2]. Proteins
involved in these processes commonly contain one or
more of specialised lipid-binding protein domains such as
FYVE [3], PH [4,5], FERM [6], C2 [7], PX [8] and others.
PX domains have first been described in p40phox and
p47phox subunits of NADPH oxidase [9]. Since then they
have been identified in a variety of proteins that are
involved in cell signalling and membrane trafficking. The
involvement of PX domains in these cellular processes
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stems from their capacity to bind phosphoinositides that
are not only integral components of many cellular mem-
branes but are also utilized as secondary messengers [1,2].
Phosphoinositides (PIs) form a class of membrane phos-
pholipids whose basic structure is termed phosphatidyli-
nositol (PtdIns). PtdIns consists of a diacylglycerol linked
by a phosphodiester bond to position 1 of an inositol
head group. Other phosphoinositides are formed by
phosphorylation of the inositol group at position 3, 4 or
5 or combination of these sites. These 3, 4, and/or 5-
phosphorylated PtdIns derivatives are metabolized by the
specific lipid phosphatases generating a dynamic pool of
variously phosphorylated PtdIns species in the cell [10].
Protein-binding to the specific PIs, via a lipid-binding
domain, not only directs the subcellular localisation of
that protein but crucially it can also affect its biological
activity [11-13].
PX domain-harbouring proteins exhibit different lipid
binding specificities. For example, it was reported that
Vam7p [14], sorting nexin 3 [15] and p40phox [16,17]
bind PtdIns3P. P47phox  exhibits specificity for
PtdIns(3,4)P2 [16], yeast protein Bem1p binds PtdIns4P
[18], while the PX domain of PI3K-C2α preferentially
binds PtdIns(4,5)P2  [19]. The structural basis for this
property that PX domains differentiate between PIs,
together with functional implications of their lipid-bind-
ing specificities, has led to a great deal of interest. The first
insight into the lipid-binding mode of PX domains came
from the structure of p40phox in complex with PtdIns3P
[20]. The structure revealed specific basic residues that are
involved in interactions with phosphate groups at the
inositol positions 1 and 3. Further structure reports of
other PtdIns3P-binding proteins have shown that analo-
gous residues were also present in their PX domains
[21,22]. The crystal structure of p47phox revealed a phos-
phatidic acid site in addition to the main PtdIns(3,4)P2
binding region [23]. More recently, the structures of yeast
Bem1p [24] and human PI3K-C2α [25] PX domains, two
domains that do not bind 3-phosphorylated PtdIns, have
been reported addressing the origin of their lipid-binding
specificity. These two reports were elegantly comple-
mented by membrane binding analyses providing a
strong link between detailed structural and functional
characteristics of PX domains.
We now report two structures of the PI3K-C2α PX domain
that were crystallised in a new crystal form, P3121, and
refined to 2.1 Å and 2.5 Å respectively. The two structures
provide further insight into the possible mode of
PtdIns(4,5)P2 binding. The family of PI 3-kinases (PI3Ks)
catalyses phosphorylation of the cytosol-oriented inositol
head group at the 3-hydroxyl position [26,27]. Four
known lipid products that act as secondary messengers are
generated by different classes of PI 3-kinases. It has been
demonstrated that the in vitro substrates of Class II PI 3-
kinases, comprising PI3K-C2α, PI3K-C2β and PI3K-C2γ,
are PtdIns and PtdIns4P [28,29]. While all PI3Ks must
interact with phosphoinositides as phosphorylation sub-
strates within the catalytic domain active site, membrane-
associated class II PI3Ks are unique in that they addition-
ally contain PX and C2 domains appended to the C-termi-
nus of the kinase domain [30]. Curiously, deletion of
either the C-terminal C2 domain or the PX domain from
PI3K-C2α does not affect the subcellular localisation of
this enzyme and the cellular function of these apparent
structural embellishments remains unresolved [31].
Class II PI3Ks are activated by the range of stimuli such as
chemokines [32], cytokines [33] and growth factors [34].
PI3K-C2α specifically can be activated by clathrin, regulat-
ing clathrin assembly [35] and clathrin-mediated mem-
brane trafficking [36]. This enzyme was also identified as
required for ATP-dependent priming of neurosecretory
granule exocytosis [37] and as vital in vascular smooth-
muscle contraction [38]. Recently, it was demonstrated
that PI3K-C2α contributes to insulin-induced transloca-
tion of the glucose transporter GLUT4 to the plasma
membrane, underlining a definitive role of PI3K-C2α in
insulin signalling [39]. Furthermore PI3K-C2α also trans-
locates to the plasma membrane upon insulin stimulation
[39]. The two structures of PI3K-C2α PX domain
described here provide a more complete picture of
PtdIns(4,5)P2  binding-site and allow interpretation of
some of the available mutagenesis data describing the
membrane penetration properties of PI3K-C2α PX
domain as reported by Stahelin et al [25]. In addition, the
significant variation in the conformation of the PI-bind-
ing loops in the two structures, due to a putative ligand
found in one of the PtdIns(4,5)P2 binding-sites, demon-
strates explicitly the intrinsic conformational plasticity of
this protein module in the region of its ligand interaction
site.
Results
Overall structure description
Spontaneously formed crystals of PI3K-C2α PX domain
belong to P3121 space group with cell dimensions of a =
b = 56.9 Å and c = 93.0 Å, containing one molecule of the
PX domain in the asymmetric unit. The molecule packs in
a very different fashion when compared to previously
reported structure that crystallised in space group P 4 3 2
(a= 116 Å). In both crystal forms, symmetrically related
molecules do not form extensive surface residue contacts
(Vm = 3.2 Å 3/Da in P3121 cell). The conformations of the
two loops that are implicated in ligand binding (discussed
below) appear to not be affected by crystal packing with
exception of the β1-β2 turn (residues 1434–1438) which
in our higher resolution structure comes in close contactBMC Structural Biology 2008, 8:13 http://www.biomedcentral.com/1472-6807/8/13
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with symmetrically related residues from the neighbour-
ing molecule.
The PI3K-C2α PX domain folds into the canonical PX
polypeptide chain topology comprising a three-stranded
β-sheet meander that packs against a subdomain of 3 α-
helices (Figure 1). Distinct features of this domain are the
PI binding/membrane penetrating loop (residues
1488–1497) and β1-β2 turn which also contributes to for-
mation of the PI binding site. The membrane penetrating
loop is sometimes referred to as the PPII/α2 loop, as this
region is preceded by a type-II poly-proline helix. We
solved the structure of PI3K-C2α PX domain by molecular
replacement using the human P47phox PX domain struc-
ture as a model template, as at that time the structure by
Stahelin et al was not available. Our search model did not
include any of the loops connecting the secondary struc-
ture elements as these belong to the regions of poor
sequence similarity with the template model. Overall, the
PX domain of PI3K-C2α shares 25 % sequence identity
with human P47phox of NADPH oxidase. As the refine-
ment of the replacement solutions proceeded we were
able to build the residues that were missing in the starting
model. Particularly challenging was building the α1-α2
connection as this region has weak sequence homology
and is 6 residues shorter in PI3K-C2α PX domain com-
pared to P47phox.
From the first electron density maps it became apparent
that electron density at the side chain for residue 1450 did
not correspond to that of tryptophan as expected based on
the predicted amino acid sequence. In fact the electron
density strongly suggested that the side chain is that of an
arginine. At that stage we sequenced the full length of the
several clones of the DNA construct used for the prepara-
tion of the protein and confirmed that indeed that residue
was arginine. In addition residue 1464 was found to be an
aspartate in place of the anticipated valine based on the
human sequence NP_002636, GI:4505799; this side
chain fitted much better in the electron density maps. The
discrepancy with reported protein sequence NP_002636
was also noted by Stahelin et al [25] which commented
on a possible data base error. Interestingly, the amino acid
sequence that fits best with the data is 100 % identical to
the PI3K-C2α sequence of Pongo pygmaeus,
GI:73921535. On the other hand the DNA sequence is an
exact match to human cDNA clone MGC:142218
IMAGE:8322710 and in the most recent ENSEMBL entry
(Oct 2007) this discrepancy was corrected with the refer-
ence to SNPS annotation as variable positions refSNP ID:
rs1065446 and refSNP ID: rs1143107. The capacity to rec-
ognize a different side chain in our initial electron-density
map was taken as a validation of our molecular replace-
ment solution.
The model obtained based on the 2.5 Å data contains
coordinates for residues 1421–1532 of the domain and an
additional GSHH tag-derived sequence at the C-terminus.
Residues 1490, 1491 and 1493–1496 were modelled as
alanines since their side-chains were not clearly visible in
the electron-density maps. This model, which we refer to
here as 'structure B', was refined to an Rfactor/Rfree of 0.231/
0.311. Structure A was obtained from the 2.1 Å data set
and unlike in structure B we were unable to determine the
positions of the main chain atoms for residues 1490,
1491 and 1492; these atoms were not included in the final
model. This final model additionally contained six glyc-
erol molecules and 92 water molecules and is refined to
an Rfactor/Rfree of 0.235/0.280.
Comparison with other PX domain structures
The core secondary structure elements superimpose
closely (Cα RMSD = 0.61 Å) with previously reported
PI3K-C2α PX structure (2IWL) which was determined by
SIR methods. While previously the regions of the domain
involved in PI binding were disordered, the two structures
that we have obtained provide a more complete model for
these parts of the molecule. Overlay of the two structures
(Figure 2A) shows that the polypeptides used for the crys-
tallisations differ: while we have used the polypeptide that
spans residues 1421–1532 of the protein, 2IWL structure
is of a longer polypeptide that corresponds to the region
1405–1541 (with residues 1409–1539 visible in the struc-
Cartoon diagram of PI3K-C2α PX domain Figure 1
Cartoon diagram of PI3K-C2α PX domain. The colour 
scheme is based on the secondary structure with helices 
shown in blue and β-strands in purple.
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ture). The two polypeptides crystallised in distinctly dif-
ferent space groups: P 31 2 1 and P 4 3 2 respectively,
placing the two molecules in very different packing envi-
ronments. The longer N-terminus, which does not com-
prise a part of a canonical globular PX domain structure,
cannot be accommodated within the unit cell that
describes the structures that we report. Similarly, the pack-
ing arrangement in P 4 3 2 symmetry equivalent to that of
2IWL structure cannot accommodate the conformations
of the phosphoinositide-binding loops that we observe.
Our two new structures, A and B, are however not identi-
cal: they have two significantly different conformations of
the putative PI binding region. Structure B has a more
open PI binding site with the PPII/α2 loop and β1-β2 turn
presenting conformations similar to that previously seen
in the yeast PX domain protein Grd19p. On the other
hand, the higher resolution structure, structure A, exhibits
a conformation that gives a more closed appearance of the
PI binding cavity, as if the PPII/α2 loop has collapsed to
close the binding site. The conformations of the two bind-
ing sites and the comparison with the Grd19p protein are
shown in Figure 2. Although the PPII/α2 loop in the
higher resolution structure still contains significant disor-
der sufficient residues are visible in the structure to pro-
vide a clear indication of the overall shape of the binding
site. The main area where the two loop conformations
diverge is after the PGFP sequence (residues 1483–1486)
giving an open or closed loop arrangement depending on
the backbone torsion angles of the following residues. The
conformational difference cannot be described by a hinge
motion as the main parts of the two loops could not be
closely superimposed. The overall appearance of the PI
binding cavity is also affected by the differing conforma-
tions of the β1-β2 loop with the largest Cα displacement
of ~13 Å compared to ~14 Å for the PPII/α2 loop. As
shown in Figure 2b, the closed conformation of structure
A is more similar to the PtdIns3P-bound Grd19p struc-
ture, while the PI3K-C2α PX structure B is closer to the un-
liganded Grd19p structure. Two different conformational
states of Grd19p have been attributed to the ligand-bind-
ing and our two PI3K-C2α PX domain structures suggest
that binding of PI ligands to the PI3K-C2α PX domain
might also be accompanied by conformational change.
C alpha traces of structures A (cyan) and B (silver) Figure 2
C alpha traces of structures A (cyan) and B (silver). a) The two structures were superimposed with the Cα trace of 2IWL [25] 
PI3K-C2α structure (magenta). Dashed line represents most likely positions for the three residues disordered and not 
observed in structure A. N and C denote the positions of the N- and C-termini of the structures A and B, while N* and C* 
point to the N- and C- terminal ends of structure 2IWL. b) Structures A and B were superimposed with the Cα trace of 
1OCU (orange), the yeast PX domain protein Grd19p and 1OCS (yellow), Grd19p protein in complex with phosphatidylinosi-
tol-3-phosphate. The phosphatidylinositol-3-phosphate is drawn as sticks coloured on atom type.
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Putative PI-binding site
Interestingly, in the 'collapsed' form observed in structure
A, the equivalent side chain of the Met1489 folds inside
the cavity with its sulphur atom positioned near the sul-
phate binding site of the 2IWL structure (Figure 3a). In
addition, the shape of the Met side chain closely resem-
bles one half of the inositol ring when modelled at that
site. In contrast, in the 'open' conformation of the loop
from structure B, the Met side chain protrudes out of the
lipid binding site. However, unaccounted electron density
was clearly visible inside the cavity of the putative PI-bind-
ing area linking to residue Arg1503 (Figure 3b). The den-
sity has a relatively flat shape and for the purpose of
illustration we have positioned a glycerol molecule within
the density in Figure 3b. We have attempted to model this
density as maleic acid, glucose, glycerol and inositol, none
of which adequately describes the density and all of which
had only a minor impact on Rfree. Presumably, an uniden-
tified component of the buffer or LB media was trapped in
the binding site of the PX domain.
The putative ligand found in the B structure delineates the
most likely ligand interaction site, and in Figure 4 we have
positioned an inositol ring to overlap with the density in
order to further discuss aspects of PI binding site. Com-
parison of the PI3K-C2α structure in this region with
P40phox or Grd19p, both of which bind 3-phosphorylated
PIs, immediately reveals that the conserved basic residues
involved in the specific interaction with the 3-phosphate
group are missing in the PI3K-C2α PX domain. Thus the
two structures reported here reinforce the observation
made by Stahelin et al, that there is a loss of positive selec-
tion for the phosphoryl-appendage at the position 3 of the
PtdIns. Namely, in place of residue Arg58 in P40phox and
equivalent Arg residues in P47phox and Grd19p that are
engaged in a specific interaction with the 3-phosphoryl
group there is residue Thr1462 in PI3K-C2α PX domain
structure. In addition, p40phox residue Arg60, which is
implicated in interaction with the 1-phosphate in
PtdIns3P-bound structure, corresponds to residue
Asp1464 in the PI3K-C2α PX domain. It was suggested by
Stahelin et al that Asp1464, a residue that is conserved in
all PI3K-C2α sequences, imposes negative selection
against 3-phosphorylated PtdIns species. Based on our
model of the inositol ring in putative ligand electron den-
sity we would suggest that this residue not only is incom-
patible with phosphate binding but that it might be
involved in specific interaction with the 3-OH and/or 2-
OH groups of PtdIns(4,5)P2 ligand. A similar type of inter-
action is present in many ribose-containing coenzyme
binding sites where acidic side chain serves the function of
discriminating between NADH and NADPH molecules
[40-42]. A specific interaction with 3(2)-OH group(s)
would orient PtdIns(4,5)P2  such that the phosphoryl
groups would be positioned for the appropriate interac-
tions with the residues of the PPII/α2 loop. In a recently
reported structure of the PX domain of Bem1p, which is
PtdIns4P-specific, the equivalent position is occupied by
PI binding pocket Figure 3
PI binding pocket. a) Ribbon representation of the structures A (cyan) and B (silver) with the (2Fo-Fc) electron density for the 
side chain of Met1489 residue in structure A. The position of a bound-sulphate in the 2IWL structure is depicted for compari-
son. b) View of ligand-binding pocket in structure B, showing glycerol modelled into 2Fo-Fc electron density that is central to 
the proposed phosphoinositide binding site. Structure B is shown as a stick model and coloured based on atom types.
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a Gln residue. However, this PX domain, while highly
selective for PtdIns4P, exhibited only modest affinity for
PtdIns4P-containing vesicles when compared to the
apparent affinity of PI3K-C2α PX domain for its cognate
PI.
In structure B, the putative ligand appears to form hydro-
gen bonds with Arg1503, a highly conserved residue in PX
domains. Modelling of an inositol ring in this site (Figure
4) shows that, with minor adjustments of torsion angles
Arg1503 would be optimally posed to interact with a
phosphoryl group at inositol position 4 and that another
residue from PPII/α2 loop would likely be involved in
interaction with the 5-phosphate.
Discussion
Variant PPII/α2 loop conformational states and 
implications for PI binding
Although the two structures reported here provide a more
complete model of the PI3K-C2α PX domain, we are still
unable to give a detailed atomic description of the PI
binding-site. However, the discrete conformational states
of the PPII/α2 loop and β1-β2 turn in our two structures,
as well as the presence of a bound ligand in one of them,
allow us to postulate that PI binding is associated with
conformational changes. A similar observation was made
for the PX domain of Grd19p although in this case a more
'closed' conformation was associated with the ligand-
bound form of the protein. To date no structures of a 4- or
5- phosphorylated PtdIns molecule bound to the binding
site of the corresponding PX proteins have been deter-
mined and hence the precise molecular basis of the PI spe-
cificity of these molecules remains unresolved. It is most
likely that the conserved residue Arg1503 is engaged in
the interaction with phosphoryl groups at these sites even
though the same residue is engaged in interaction with
non-substituted OH groups in those molecules that
exhibit strict PtdIns3P specificity. Therefore, other con-
tributors to the 4,5-phosphate binding specificity would
have to exist. We suggest that, at least in part, this specifi-
city arises from the intrinsic flexibility of the PPII/α2 loop
and β1-β2 turn as shown explicitly by our two structures
and implied by the 2IWL structure. This flexibility of the
binding site would affectively enable the molecule to
adopt a conformation required to accommodate the
phosphoryl groups at PtdIns positions 4 and 5 and to still
place Arg1503 residue at the right distance for effective
interaction. In addition, other positively charged residues
in the region would contribute to formation of the appro-
priate complementary electrostatic potential needed to
compensate for the negative charges associated with the
two phosphoryl groups. In the report by Stahelin et al,
some of the residues in this region have been mutated and
shown to impact the binding affinity of the domain. For
example, mutation of the residue Arg1503 completely
abolishes PI binding. The second most profound muta-
tion is that of Arg1493 which results in 23- fold decrease
in PtdIns(4,5)P2 binding affinity. Although we were able
to model backbone atoms for this residue in one of our
structures, the side chain for this residue is not visible in
the electron density map. Simple modelling of the Arg tor-
sion angles suggests that this side chain could fold into the
PI binding cavity and be engaged in electrostatic interac-
tion with 5-phosphoryl group of the ligand. Interestingly
Arg1488, which when mutated to Ala leads to 7-fold
decrease in PtdIns(4,5)P2 binding affinity, presents differ-
ent conformations in our two structures. In the 'closed'
structure A conformation of the PPII/α2 loop this side
chain is oriented away from the core of the domain into
the solvent region, while in the B structure with the 'open'
PPII/α2 loop conformation, it is turned more towards the
interior of the loop. This observation reinforces the
notion that ligand-binding to the PI3K-C2α PX domain is
associated with local conformational changes that would
allow for the optimal modelling of the binding site to
match the ligand regiochemistry and to complement its
electrostatic potential distribution with the residues that
form PI binding surface.
Conclusion
Our two new structures of PI3K-C2α PX domain show sig-
nificantly different conformations of the PI binding
region. These differences are attributed to the presence of
a putative ligand in the PtdIns(4,5)P2 binding cavity in
one of the crystal structures. The ligand-bound structure
Model of an inositol molecule in the proposed PI-binding site  in structure B Figure 4
Model of an inositol molecule in the proposed PI-binding site 
in structure B. Inositol was positioned into 2Fo-Fc electron 
density. Contacts to Asp1464 residue and Arg1503 residue 
are highlighted.
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exhibits an 'open' conformation of the PI binding region.
In contrast, in unliganded structure the main loop of the
PtdIns(4,5)P2 binding cavity collapses into the cavity cre-
ating a 'closed' conformation of the region. The two struc-
tures reported here together with that reported previously
by Stahelin et al, provide compelling evidence for the
plasticity of this domain which might be required to
achieve full PtdIns(4,5)P2 specificity. In addition, we sug-
gest that residue Asp1464, which is conserved in PI3K-
C2α proteins, might be involved in the specific recogni-
tion of 3- OH group within PtdIns(4,5)P2 molecule.
Methods
Protein expression, Purification and Crystallisation
The full-length PI3K-C2α gene in pBKCMV vector was
obtained from Prof Peter Shepherd's laboratory [43]. A
portion of the full length PI3K-C2α gene corresponding to
the amino acid residues 1421–1532 was amplified by
PCR methods. This gene construct was inserted into a
modified pET-21(b) vector which contained only NdeI
and BamHI cloning sites yielding the protein product
with a 6His-tag at the C-terminus together with a Gly-Ser
linker (part of BamHI cloning site). This construct was ini-
tially sequenced to confirm insertion of the fragment in-
frame and subsequently was resequenced (VWR sequenc-
ing services) to validate apparent amino acid discrepan-
cies based on the X-ray electron density maps.
Protein was expressed in BL21(DE3) cells at 37°C and
purified by Ni2+-affiinty chromatography. During the
purification procedure, it was necessary to keep concen-
tration of the protein fraction bellow 2.5 mg/ml as it was
noticed that the protein was susceptible to precipitation.
The purified protein was dialysed into a buffer containing
10 mM Na acetate pH 5.5, 6 mM DTT and 1 mM EDTA
and concentrated to 1.25 mg/ml. Initially, the protein was
prepared for NMR studies and a screen was carried out,
testing the solubility of the protein in a range of organic
acid buffers [44]. During this procedure it was noticed
that protein precipitated or crystallized under many con-
ditions and further screens were designed to increase the
yield and size of the crystals. Final crystals were obtained
by the hanging drop method where 1 μl of reservoir solu-
tion was mixed with 3–6 μl of protein solution and
inverted over 1 ml of 0.1 M Na-maleate pH 6.0, 10–20 %
glycerol, in the reservoir. Crystals grew overnight and
achieved their final size within a few days.
Data Collection and Structure Determination
The crystals grown in the presence of 20 % glycerol were
frozen in liquid nitrogen directly prior to data collection;
otherwise the crystals were transferred into a cryoprotect-
ant solution consisting of reservoir buffer plus 20% (v/v)
glycerol before being flash-cooled in liquid nitrogen. It
was found that the crystals were heterogeneous and that,
even from the same batch of protein preparation, crystals
exhibited different diffraction power with maximum reso-
lution ranging from 3.5 Å to 1.9 Å. After screening several
crystals two data sets were collected and used to determine
the structures reported here. The first data set at 2.5 Å was
obtained in-house using a R-AXISIV image plate detector
system and Osmic mirrors. Higher resolution crystal data
(2.1 Å) on a different crystal were collected at the ESRF,
Grenoble on beamline ID-14-4. All data was processed by
DENZO and scaled by using SCALEPACK [45].
The structure was initially solved with the in-house col-
lected data set by molecular replacement using EPMR
[46]. The search model was created from the X-ray struc-
ture of the un-liganded PX subunit of p47phox NADPH oxi-
dase, PDB id 1O7K. To create a starting model, the main
loops in the structure were removed and the non-con-
served residues were substituted with alanines. The initial
molecular replacement solution was subsequently built
using TURBO [47] and refined using REFMAC [48]. 10%
of the reflections were selected for cross validation during
refinement. The poly-histidine tag and some residues in
the loop regions were not fully visible in the electron den-
sity maps and they were either excluded from the final
model or their side chains were shortened to include only
Cβ atoms. The higher resolution model also included six
glycerol molecules. The models, as evaluated by PRO-
CHECK [49], show good geometry with only 1 Gly resi-
due in L-α helical region. The data collection and
refinement statistics are shown in Table 1. The structures
and structure factors were deposited with the PDB with ID
codes 2RED and 2REA.
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